Ignite Creation Date:
2025-12-24 @ 5:45 PM
Ignite Modification Date:
2026-01-01 @ 1:08 PM
Study NCT ID:
NCT06402968
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-07
First Post:
2024-05-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Sponsor:
Zeenat Qureshi Stroke Institute
Organization:
Study Overview
Official Title:
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CLUTCH
Brief Summary:
The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: